Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Open accessAbstract
INTRODUCTION: To evaluate the efficacy of empagliflozin compared to pioglitazone in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM). METHODS: In this prospective randomized, double-blind, placebo-controlled trial, we assigned 106 patients with NAFLD and T2DM to receive empagliflozin 10 mg (n = 35), pioglitazone 30 mg (n = 34), or placebo (n = 37) for 24 weeks. Liver fat content and liver stiffness were measured using fibroscans. Body composition assessment was performed by dual-energy x-ray absorptiometry (DEXA) scans. The primary end point was change from baseline in liver steatosis, using the controlled attenuation parameter (CAP) score. RESULTS: A borderline significant decrease in CAP score was observed with empagliflozin compared to placebo, mean difference: - 29.6 dB/m (- 39.5 to - 19.6) versus - 16.4 dB/m (- 25.0 to - 7.8), respectively; p = 0.05. Using multivariate analysis, we observed a significant reduction in the placebo-corrected change in liver stiffness measurement (LSM) with empagliflozin compared to pioglitazone: - 0.77 kPa (- 1.45, - 0.09), p = 0.02, versus 0.01 kPa (95% CI - 0.70, 0.71, p = 0.98), p for comparison = 0.03. Changes in serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT), fasting insulin, homeostatic model assessment for insulin resistance (HOMA-IR), HOMA2-IR, fibrosis-4 index (FIB4 index), NAFLD fibrosis score, aspartate aminotransferase to platelet ratio index (APRI), android/gynecoid ratio (A/G ratio), and skeletal muscle index (SMI) were comparable between the two treatment groups, while significant reductions of the body weight and visceral fat area were observed only in the empagliflozin group (p < 0.001 and p = 0.01, respectively) and both were increased in the placebo and pioglitazone groups. There were no serious adverse events in either group. CONCLUSION: Treatment for 24 weeks with empagliflozin, in contrast to pioglitazone, was associated with improvement of liver steatosis and fibrosis in patients with NAFLD and T2DM. In addition, body weight and abdominal fat area were decreased in the empagliflozin group. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT), IRCT20190122042450N3.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Empagliflozin (EMPA) exhibits potential therapeutic benefits for liver steatosis.
“Empagliflozin (EMPA), a highly selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), exhibits potential therapeutic benefits for liver steatosis; however, the underlying mechanism remains incompletely elucidated.”
From SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 1× · see citing works
“Furthermore, the FIB-4 (fibrosis 4) index [39] was calculated using the following formula: FIB-4 index = [age 9 AST (units/l)]/(platelet count (9 10(9)/l) 9 [ALT (units/l)].”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · see citing works
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,198 · see citing works
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,413 · see citing works
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907 · see citing works
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · see citing works
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429 · see citing works
Eddowes, P. J., Sasso, M., Allison, M., Tsochatzis, E. A., Anstee, Q. M., Sheridan, D. A., Guha, I. N., Cobbold, J., Deeks, J. J., Paradis, V., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.042 · Cited by 1,425 · see citing works
Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study
Foucher, J. (2005) · Gut · doi:10.1136/gut.2005.069153 · Cited by 1,289 · see citing works
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069 · see citing works
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · see citing works
Adams, L. A., Sanderson, S. O., Lindor, K. D., & Angulo, P. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 908 · see citing works
Sasso, M., Beaugrand, M., de Lédinghen, V., Douvin, C., Marcellin, P., Poupon, R. Y., Sandrin, L., & Miette, V. (2010) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2010.07.005 · Cited by 864 · see citing works
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 861 · see citing works
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726 · see citing works
Magnetic Resonance Elastography for the Noninvasive Staging of Liver Fibrosis
Huwart, L., Sempoux, C. L., Vicaut, É., Salameh, N., Annet, L., Danse, É., Peeters, F., ter Beek, L. C., Rahier, J., Sinkus, R., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.076 · Cited by 726 · see citing works
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662 · see citing works
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study
Poonawala, A., Nair, S. P., & Thuluvath, P. J. (2000) · Hepatology · doi:10.1053/jhep.2000.17894 · Cited by 566 · see citing works
Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 497 · see citing works
Mantovani, A., Petracca, G., Beatrice, G., Tilg, H., Byrne, C. D., & Targher, G. (2021) · Gut · doi:10.1136/gutjnl-2020-322572 · Cited by 481 · see citing works
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. C. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 471 · see citing works
Nobili, V., Vizzutti, F., Arena, U., Abraldeṣ, J. G., Marra, F., Pietrobattista, A., Fruhwirth, R., Marcellini, M., & Pinzani, M. (2008) · Hepatology · doi:10.1002/hep.22376 · Cited by 429 · see citing works
Degos, F., Perez, P., Roche, B., Mahmoudi, A., Asselineau, J., Voitot, H., & Bédossa, P. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.035 · Cited by 429 · see citing works
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 398 · see citing works
Shimizu, M., Suzuki, K., Kato, K., Jojima, T., Iijima, T., Murohisa, T., Iijima, M., Takekawa, H., Usui, I., Hiraishi, H., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13520 · Cited by 393 · see citing works
Salgado, A. L. F. D. A., Carvalho, L. D., Oliveira, A. C., Santos, V. N. D., Vieira, J. G., & Parise, E. R. (2010) · Arquivos de Gastroenterologia · doi:10.1590/s0004-28032010000200009 · Cited by 315 · see citing works
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 312 · see citing works
Le, M. H., Devaki, P., Ha, N. B., Jun, D. W., Te, H. S., Cheung, R. C., & Nguyen, M. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173499 · Cited by 287 · see citing works
Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 280 · see citing works
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Pοlyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277 · see citing works
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
Dai, W., Ye, L., Liu, A., Wen, S. W., Deng, J., Wu, X. Y., & Lai, Z. (2017) · Medicine · doi:10.1097/md.0000000000008179 · Cited by 268 · see citing works
Hirose, H., Kawai, T., Yamamoto, Y., Taniyama, M., Tomita, M., Matsubara, K., Okazaki, Y., Ishii, T., Oguma, Y., Takei, I., et al. (2002) · Metabolism · doi:10.1053/meta.2002.30506 · Cited by 235 · see citing works
Komiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., Yamaguchi, S., Kanno, K., & Ogawa, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151511 · Cited by 230 · see citing works
Zarski, J., Stürm, N., Guechot, J., Paris, A., Zafrani, E., Asselah, T., Boisson, R. C., Bosson, J., Guyader, D., Renversez, J., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.024 · Cited by 211 · see citing works
Liver and diabetes. A vicious circle
Loria, P., Lonardo, A., & Anania, F. A. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01031.x · Cited by 206 · see citing works
Taheri, H., Malek, M., Ismail‐Beigi, F., Zamani, F., Sohrabi, M., Babaei, M. R., & Khamseh, M. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01498-5 · Cited by 197 · see citing works
Self-citationShibuya, T., Fushimi, N., Kawai, M., Yoshida, Y., Hachiya, H., Ito, S., Kawai, H., Ohashi, N., & Mori, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13061 · Cited by 192 · see citing works
Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5477-1 · Cited by 191 · see citing works
British Journal of Medicine and Medical Research
Lanza, A., Scognamiglio, F., Femiano, F., & Lanza, M. (2017) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr · Cited by 178 · see citing works
Pathophysiology of Non Alcoholic Fatty Liver Disease
Petta, S., Gastaldelli, A., Rebelos, E., Bugianesi, E., Messa, P., Miele, L., Svegliati‐Baroni, G., Valenti, L. V. C., & Bonino, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122082 · Cited by 170 · see citing works
Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115616901 · Cited by 168 · see citing works
Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139 · see citing works
Sasaki, T., Sugawara, M., & Fukuda, M. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12851 · Cited by 119 · see citing works
Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review
Severson, T. J., Besur, S. V., & Bonkovsky, H. L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i29.6742 · Cited by 105 · see citing works
Lee, Y., Kim, J. H., Kim, S. R., Jin, H. Y., Rhee, E., Cho, Y. M., & Lee, B. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.1.60 · Cited by 104 · see citing works
NAFLD—the next global epidemic
Ray, K. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.197 · Cited by 96 · see citing works
Fujii, H., Imajo, K., Yoneda, M., Nakahara, T., Hyogo, H., Takahashi, H., Hara, T., Tanaka, S., Sumida, Y., Eguchi, Y., et al. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14595 · Cited by 94 · see citing works
Roulot, D. M., Roudot‐Thoraval, F., Nkontchou, G., Kouacou, N., Costes, J., Elourimi, G., Clésiau, H. L., Ziol, M., & Beaugrand, M. (2017) · Liver International · doi:10.1111/liv.13481 · Cited by 94 · see citing works
Esther Phielix, E., Szendroedi, J., & Roden, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.006 · Cited by 91 · see citing works
Therapy of nonalcoholic fatty liver disease: current status.
Duvnjak, M., Tomašić, V., Gomerčić, M., Duvnjak, L. S., Baršić, N., & Lerotić, I. (2009) · PubMed · Cited by 82 · see citing works
Ohki, T., Isogawa, A., Toda, N., & Tagawa, K. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0383-1 · Cited by 79 · see citing works
Takase, T., Nakamura, A., Miyoshi, H., Yamamoto, K., & Atsumi, T. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0295 · Cited by 76 · see citing works
Blonde, L., Stenlöf, K., Fung, A., Xie, J., Canovatchel, W. J., & Meininger, G. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1169894 · Cited by 71 · see citing works
Seko, Y., Sumida, Y., Sasaki, K., Itoh, Y., Iijima, H., Hashimoto, T., Ishii, S., & Inagaki, N. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1364-8 · Cited by 70 · see citing works
Grgurević, I., Podrug, K., Mikolašević, I., Kukla, M., Madir, A., & Tsochatzis, E. A. (2020) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2020/9181368 · Cited by 68 · see citing works
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66 · cited 1× · see citing works
“However, despite the role of incretin hormones in NAFLD pathogenesis [17] and various interventions targeting the gut-pancreas-liver axis, in NASH treatment no approved treatment is currently available [17, 18].”
BackgroundKurinami, N., Sugiyama, S., Yoshida, A., Hieshima, K., MIYAMOTO, F., Kajiwara, K., Jinnouch, K., Jinnouchi, T., & Jinnouchi, H. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.017 · Cited by 62 · see citing works
Thiazolidinediones and the liver in humans
Yki‐Järvinen, H. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283321d37 · Cited by 59 · see citing works
Ballestri, S., Capitelli, M., Fontana, M. C., Arioli, D., Romagnoli, E., Graziosi, C., Lonardo, A., Marietta, M., Dentali, F., & Cioni, G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01307-z · Cited by 59 · see citing works
You, S. C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i4.1158 · Cited by 57 · see citing works
Ohta, A., Kato, H., Ishii, S., Sasaki, Y., Nakamura, Y., Nakagawa, T., Nagai, Y., & Tanaka, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363888 · Cited by 56 · see citing works
Banini, B. A., & Sanyal, A. J. (2016) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s18885 · Cited by 52 · see citing works
Doycheva, I., Patel, N. S., Peterson, M. R., & Loomba, R. S. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.10.008 · Cited by 51 · see citing works
Non-alcoholic fatty liver disease: a diabetologist’s perspective
Pappachan, J. M., Antonio, F. A., Edavalath, M., & Mukherjee, A. (2013) · Endocrine · doi:10.1007/s12020-013-0087-8 · Cited by 50 · see citing works
Seino, Y., Yabe, D., Sasaki, T., Fukatsu, A., Imazeki, H., Ochiai, H., & Sakai, S. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12694 · Cited by 50 · see citing works
Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
Miyake, T., Yoshida, S., Furukawa, S., Sakai, T., Tada, F., Senba, H., Yamamoto, S., Koizumi, Y., Yoshida, O., Hirooka, M., et al. (2018) · Open Medicine · doi:10.1515/med-2018-0059 · Cited by 49 · see citing works
Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus.
Ribola, F. A., Cançado, F. B., Schoueri, J. H. M., Toni, V. F. D., Medeiros, V. H. R., & Feder, D. (2017) · PubMed · Cited by 44 · see citing works
Shao, S.-C., Kuo, L.-T., Chien, R.-N., Hung, M.-J., & Lai, E. C.-C. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001956 · Cited by 43 · see citing works
Revista de Gastroenterología de México 2008
Editores, L. (2008) · Revista Portuguesa de Pneumologia · Cited by 43 · see citing works
Hsing, J. C., Nguyen, M. H., Yang, B., Yan, M., Han, S. S., Pung, E., Winter, S. J., Zhao, X., Gan, D., Hsing, A. W., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1392 · Cited by 39 · see citing works
Tanaka, K., Takahashi, H., Hyogo, H., Ono, M., Oza, N., Kitajima, Y., Kawanaka, M., Chayama, K., Saibara, T., Anzai, K., et al. (2018) · Hepatology Research · doi:10.1111/hepr.13282 · Cited by 37 · see citing works
Bouchi, R., Nakano, Y., Ohara, N., Takeuchi, T., Murakami, M., Asakawa, M., Sasahara, Y., Numasawa, M., Minami, I., Izumiyama, H., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0384-7 · Cited by 33 · see citing works
Arase, Y., Shiraishi, K., Anzai, K., Sato, H., Teramura, E., Tsuruya, K., Hirose, S., Deguchi, R., Toyoda, M., Mine, T., et al. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00785-6 · Cited by 32 · see citing works
Ting, Y., Wong, S., Zaini, A. A., Mohamed, R. B., & Jalaludin, M. Y. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00491 · Cited by 27 · see citing works
Velasco, J. A. V.-R., García-Jiménez, E. S., García‐Zermeño, K. R., Morel-Cerda, E. C., Aldana-Ledesma, J. M., Castro‐Narro, G., Cerpa‐Cruz, S., Tapia-Calderón, D. K., Mercado-Jauregui, L. A., & Contreras-Omaña, R. (2019) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2019.05.004 · Cited by 21 · see citing works
Kusunoki, M., Natsume, Y., Sato, D., Tsutsui, H., Miyata, T., Tsutsumi, K., Suga, T., & Oshida, Y. (2016) · Drug Research · doi:10.1055/s-0042-111515 · Cited by 19 · see citing works
Kusunoki, M., Natsume, Y., Miyata, T., Tsutsumi, K., & Oshida, Y. (2018) · Drug Research · doi:10.1055/a-0585-0145 · Cited by 17 · see citing works
Yen, Y., Chen, J., Cheng, B., Chen, J., Chang, K., Tseng, P., Wu, C., Tsai, M., Lin, M., & Hu, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176027 · Cited by 17 · see citing works
Katsuyama, H., Hakoshima, M., Iijima, T., Adachi, H., & Yanai, H. (2020) · Journal of Endocrinology and Metabolism · doi:10.14740/jem632 · Cited by 9 · see citing works
Khan, R. S., & Newsome, P. N. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05573-y · Cited by 6 · see citing works
Degos, F., Perez, P., Asselineau, J., & Bédossa, P. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.015 · Cited by 5 · see citing works
Increased Hemoglobin A1c Correlates with Increased Liver Stiffness in a Mexican-American Population
Watt, G. P., Lee, M., Pan, J., Fallon, M. B., McCormick, J. B., & Fisher‐Hoch, S. P. (2018) · Diabetes · doi:10.2337/db18-2391-pub · Cited by 2 · see citing works
Bileaflet valve replacement: complications and costs.
Migliaccio–Walle, K., Klittich, W. S., Banks, J., O'Brien, J. A., & Jaime, J. (1996) · PubMed · Cited by 2 · see citing works
Mathur, P., Mathur, S., Punjabi, P., Vaishnav, R., & Mathur, M. (2016) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2016/21556 · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [9]Petta S Gastaldelli A Rebelos E Bugianesi E Messa P Miele L Svegliati-Baroni G Valenti L Bonino F Pathophysiology of nonalcoholic fatty liver disease Int J Mol Sci 2016 17 12 2082 PMC5187882 27973438
Cited by
Sorted by citations
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 370 · see citing works
Negi, C. K., Babica, P., Bajard, L., Vašků, J. B., & Tarantino, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 193 · see citing works
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Ανδρουτσάκος, Θ., Ansari, N. N., Bakasis, A., Kyrou, I., EFSTATHOPOULOS, E. P., Randeva, H. S., & Kassi, E. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063107 · Cited by 172 · see citing works
Lin, J., Huang, Y., Xu, B., Gu, X., Huang, J., Sun, J., Jia, L., Jiang, H., Huang, C., Wei, X., et al. (2025) · BMJ · doi:10.1136/bmj-2024-083735 · Cited by 145 · see citing works
Shen, Y., Cheng, L., Xu, M., Wang, W., Wan, Z., Xiong, H., Guo, W., Cai, M., & Xu, F. L. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155657 · Cited by 118 · see citing works
Pan, R., Zhang, Y., Wang, R., Xu, Y. Q., Ji, H., & Zhao, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279889 · Cited by 113 · see citing works
Zhang, S., Qi, Z., Wang, Y., Song, D., & Zhu, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1203666 · Cited by 86 · see citing works
Lopez, A., & Pajimna, J. A. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-52603-5 · Cited by 91 · see citing works
Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 75 · see citing works
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 74 · see citing works
Abdelhamid, A. M., Saber, S., Youssef, M. E., Gaafar, A. G. A., Eissa, H., Abdel-Dayem, M. A., Alqarni, M., Batiha, G. E., Obaidullah, A. J., Shahien, M. A., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112455 · Cited by 63 · see citing works
SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation
Liu, W., You, D., Lin, J., Zou, H., Zhang, L., Luo, S., Yuan, Y., Wang, Z., Qi, J., Wang, W., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.08.005 · Cited by 61 · see citing works
Feijóo‐Bandín, S., Aragón‐Herrera, A., Otero-Santiago, M., Anido‐Varela, L., Moraña‐Fernández, S., Tarazón, E., Roselló‐Lletí, E., Portolés, M., Gualillo, O., González‐Juanatey, J. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105634 · Cited by 60 · see citing works
Beygi, M., Ahi, S., Zolghadri, S., & Stanek, A. (2024) · Nutrients · doi:10.3390/nu16142220 · Cited by 64 · see citing works
Bea, S., Ko, H. Y., Bae, J. H., Cho, Y. M., Chang, Y., Ryu, S., Byrne, C. D., & Shin, J. (2024) · Gut · doi:10.1136/gutjnl-2024-332687 · Cited by 59 · see citing works
Wang, Z., Huiqing, D., Zhao, Y., Ren, Y., Ma, C., Chen, H., Li, M., Tian, J., Xue, C., Long, G., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111430 · Cited by 54 · see citing works
Cheung, K. S., Ng, H. Y., Hui, R. W. H., Lam, L. K., Mak, L., Ho, Y. C., Tan, J. T., Chan, E. W., Seto, W., Yuen, M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000855 · Cited by 56 · see citing works
Gries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 55 · see citing works
Wang, X., Wu, N., Sun, C., Jin, D., & Lu, H. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01085-y · Cited by 50 · see citing works
Hüttl, M., Marková, I., Miklánková, D., Zapletalová, I., Poruba, M., Haluzı́k, M., Vaněčková, I., & Malínská, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111513 · Cited by 51 · see citing works
Jin, Z., Yuan, Y., Chen, Z., Liu, S., & Weng, H. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108558 · Cited by 49 · see citing works
Chan, W., Tan, S.-S., Chan, S.-P., Lee, Y. Y., Tee, H., Mahadeva, S., Goh, K., Ramli, A. S., Mustapha, F. I., Kosai, N. R., et al. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15787 · Cited by 46 · see citing works
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 50 · see citing works
Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
Lee, Y., Lim, S. K., & Davies, M. J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01170-4 · Cited by 55 · see citing works
The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
El-Hini, S. H., Wahsh, E. A., Elberry, A. A., Ameen, N. F. E., Saedii, A. A. F., Refaie, S. M., Elsayed, A. A., & Rabea, H. (2022) · Pharmaceuticals · doi:10.3390/ph15121516 · Cited by 49 · see citing works
Chadha, M. D., Das, A. K., Deb, P., Gangopadhyay, K. K., Joshi, S., Kesavadev, J., KOVIL, R. R., Kumar, S., Misra, A., & Mohan, V. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01219-x · Cited by 45 · see citing works
Bica, I.-C., Stoica, R. A., Salmen, T., Janež, A., Volčanšek, Š., Popovic, D. S., Muzurović, E. M., Rizzo, M., & Stoian, A. P. (2023) · Medicina · doi:10.3390/medicina59061136 · Cited by 42 · see citing works
Caturano, A., Galiero, R., Loffredo, G., Vetrano, E., Medicamento, G., Acierno, C., Rinaldi, L., Marrone, A., Salvatore, T., Monda, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020322 · Cited by 42 · see citing works
Abdelhamid, A. M., Youssef, M. E., El-Fattah, E. E. A., Gobba, N. A., Gaafar, A. G. A., Girgis, S., Shata, A., Abdel-Moneim, A.-M. H., El-Ahwany, E. G., Amin, N. A., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120070 · Cited by 42 · see citing works
Kongmalai, T., Srinonprasert, V., Anothaisintawee, T., Kongmalai, P., McKay, G. J., Attia, J., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1182037 · Cited by 41 · see citing works
Gu, Y., Sun, L., Zhang, W., Kong, T., Zhou, R., He, Y., Deng, C., Yang, L., Kong, J., Chen, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1102792 · Cited by 46 · see citing works
Zhang, Y., Liu, X., Zhang, H., & Wang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.836455 · Cited by 42 · see citing works
Deng, M., Wen, Y., Yan, J., Fan, Y., Wang, Z., Zhang, R., Ren, L., Ba, Y., Wang, H., Lü, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03129-6 · Cited by 40 · see citing works
Yan, H., Huang, C., Shen, X., Li, J., Zhou, S., & Li, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.923606 · Cited by 37 · see citing works
Lee, C., Mak, L., Tang, E. H. M., Lui, D. T. W., Mak, J. H., Li, L., Wu, T., Chan, W., Yuen, M., Lam, K. S. L., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000404 · Cited by 35 · see citing works
Chung, S. W., Moon, H.-S., Shin, H., Han, H., Park, S., Cho, H., Park, J., Hur, M. H., Park, M. K., Won, S., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000837 · Cited by 36 · see citing works
Perakakis, N., Chrysafi, P., Feigh, M., Veidal, S. S., & Mantzoros, C. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126332 · Cited by 34 · see citing works
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Zachou, M., Flevari, P., Ansari, N. N., Varytimiadis, C., Kalaitzakis, E., Kassi, E. N., & Ανδρουτσάκος, Θ. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03586-1 · Cited by 36 · see citing works
SGLT2 inhibitors and AMPK: The road to cellular housekeeping?
Safaie, N., Masoumi, S., Alizadeh, S., Mirzajanzadeh, P., Nejabati, H., Hajiabbasi, M., Alivirdiloo, V., Basmenji, N. C., Radvar, A. D., Majidi, Z., et al. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3922 · Cited by 33 · see citing works
Sun, L., Deng, C., Gu, Y., He, Y., Yang, L., & Shi, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101876 · Cited by 31 · see citing works
Effects and potential mechanisms of IGF1/IGF1R in the liver fibrosis: A review
Gui, R., Li, W., Li, Z., Wang, H., Wu, Y., Jiao, W., Zhao, G., Shen, Y., Wang, L., Zhang, J., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126263 · Cited by 30 · see citing works
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Makri, E. S., Goulas, A., & Pοlyzos, S. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174272 · Cited by 31 · see citing works
Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
Zhou, P., Tan, Y., Hao, Z., Xu, W., Zhou, X., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1144838 · Cited by 30 · see citing works
Luo, Q., Wei, R., Cai, Y., Zhao, Q., Liu, Y., & Liu, W. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.793203 · Cited by 28 · see citing works
Liu, X., Chen, Y., Liu, T., Cai, L., Yang, X., & Mou, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1115321 · Cited by 27 · see citing works
Khamseh, M. E., Malek, M., Jahangiri, S., Nobarani, S., Hekmatdoost, A., Salavatizadeh, M., Soltanieh, S., Chehrehgosha, H., Taheri, H., Montazeri, Z., et al. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08309-9 · Cited by 26 · see citing works
Self-citationEmpagliflozin: a potential anticancer drug
Wu, W., Wang, Y., Xie, J., & Fan, S. (2023) · Discover Oncology · doi:10.1007/s12672-023-00719-x · Cited by 23 · see citing works
Cheng, P., Chen, W., Hou, C. J., Lin, C., Chang, M., Wang, C., Chang, W., Wang, C., Lin, C., Hung, C., et al. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0315 · Cited by 23 · see citing works
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 24 · see citing works
Attaran, F., Emami, S., Sohrabi, M., Malek, M., Ajdarkosh, H., Khoonsari, M., Ismail-Beigi, F., & Khamseh, M. E. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02948-4 · Cited by 22 · see citing works
Self-citationLi, H., Hou, Y., Xin, W., Ding, L., Yang, Y., Zhang, Y., Wu, W., Wang, Z., & Ding, W. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107647 · Cited by 22 · see citing works
Perdomo, C. M., Garcı́a-Fernández, N., & Escalada, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10092040 · Cited by 21 · see citing works
Heo, Y.-J., Lee, N., Choi, S., Jeon, J., Han, S. J., Kim, D. J., KANG, Y. Y., Lee, K. W., & Kim, H. J. (2022) · Biomedicines · doi:10.3390/biomedicines10051032 · Cited by 21 · see citing works
Pokharel, A., Sudhamshu, K. C., Thapa, P., Karki, N., Shrestha, R., Jaishi, B., & Paudel, M. S. (2021) · Cureus · doi:10.7759/cureus.16687 · Cited by 21 · see citing works
SGLT-2 inhibitors as novel treatments of multiple organ fibrosis
Hu, J.-P., Teng, J., Hui, S., & Liang, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29486 · Cited by 21 · see citing works
Hameed, I., Hayat, J., Marsia, S., Samad, S. A., Khan, R., Siddiqui, O. M., Khan, M. O., Malik, S., Fatima, K., Fudim, M., et al. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102111 · Cited by 19 · see citing works
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Xu, R., Lian, D., Xie, Y., Chen, Z., Wang, Y., Mu, L., Wang, Y., & Zhang, B. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807134 · Cited by 20 · see citing works
Miklánková, D., Marková, I., Hüttl, M., & Malínská, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1393946 · Cited by 19 · see citing works
Khaliq, A., Badshah, H., Shah, Y., Rehman, I. U., Khan, K. U., Ming, L. C., & Cheng, M. H. (2024) · Medicine · doi:10.1097/md.0000000000040356 · Cited by 20 · see citing works
Zhang, F., Pan, X., Zhang, X., & Tong, N. (2023) · Obesity Reviews · doi:10.1111/obr.13675 · Cited by 18 · see citing works
Armandi, A., Bespaljko, H., Mang, A., Huber, Y., Michel, M. S., Labenz, C., Galle, P. R., Neerukonda, M., Bugianesi, E., Schuppan, D., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17941 · Cited by 18 · see citing works
Shojaei, F., Erfanifar, A., Kalbasi, S., Nikpour, S., & Gachkar, L. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01882-8 · Cited by 17 · see citing works
Amin, M. A., Sadik, N. A., Saad, H. A., Fawzy, M., & Elsheimy, H. A. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-03902-w · Cited by 21 · see citing works
Al-Shargi, A., Kholy, A. A. E., Adel, A., Hassany, M., & Shaheen, S. M. (2023) · Biomedicines · doi:10.3390/biomedicines11113074 · Cited by 17 · see citing works
Weng, M., Yang, P., Liu, P.-F., Chang, C.-H., Lee, M., Sheu, J., & Nien, H. (2024) · Hepatology International · doi:10.1007/s12072-024-10758-3 · Cited by 16 · see citing works
Atherosclerosis and Non-Alcoholic Fatty Liver Disease
Balta, Ş. (2022) · Angiology · doi:10.1177/00033197221091317 · Cited by 16 · see citing works
Fakhrolmobasheri, M., Abhari, A. P., Manshaee, B., Heidarpour, M., Shafie, D., Mohammadbeigi, E., Mozafari, A. M., & Mazaheri‐Tehrani, S. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01981-1 · Cited by 17 · see citing works
Jahangiri, S., Malek, M., Kalra, S., & Khamseh, M. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01481-7 · Cited by 16 · see citing works
Self-citationElseweidy, M. M., Ali, A. A., Hassanin, S. M., & Mahmoud, Y. K. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02826-6 · Cited by 16 · see citing works
Lin, Y., Zhang, Z., Zhong, J.-Q., Wang, Z., Peng, Y.-T., Lin, Y.-M., Zhang, H.-P., & Tian, J.-Q. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302155 · Cited by 16 · see citing works
Kawaguchi, T., Murotani, K., Kajiyama, H., Obara, H., Yamaguchi, H., Toyofuku, Y., Kaneko, F., Seino, Y., & Uchida, S. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02122-x · Cited by 17 · see citing works
Xu, R., Liu, B., & Zhou, X. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.017 · Cited by 15 · see citing works
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 17 · see citing works
Suki, M., Imam, A., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., Sackran, J., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18081118 · Cited by 14 · see citing works
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 14 · see citing works
Hooshmand Gharabagh, L., Shargh, A., Mohammad Hosseini Azar, M. R., & Esmaeili, A. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102279 · Cited by 13 · see citing works
Ito, D., Inoue, K., Saito, D., Hamaguchi, K., Kaneko, K., Sumita, T., Inukai, K., Inoue, I., & Shimada, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01176-x · Cited by 13 · see citing works
Tang, X., Zhang, H., Wang, X., & Yang, D. (2022) · African Health Sciences · doi:10.4314/ahs.v22i3.42 · Cited by 12 · see citing works
Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11 · see citing works
Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Risk of HF and AF
Ohno, R., Kaneko, H., Suzuki, Y., Okada, A., Matsuoka, S., Ueno, K., Fujiu, K., Michihata, N., Jo, T., Takeda, N., et al. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.08.003 · Cited by 11 · see citing works
Wang, H., Ma, Q., Chen, Y., Luo, L., Ye, J., & Zhong, B. (2024) · Obesity Reviews · doi:10.1111/obr.13727 · Cited by 13 · see citing works
Ntikoudi, A., Papachristou, A., Tsalkitzi, A., Margari, N., Evangelou, E., & Vlachou, E. D. (2025) · Diabetology · doi:10.3390/diabetology6040023 · Cited by 12 · see citing works
Sun, C., Goh, G. B., Chow, W. C., Chan, W., Wong, G. L., Seto, W., Huang, Y., Lin, H.-C., Lee, H. W., Lee, H. W., et al. (2023) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2023.08.004 · Cited by 10 · see citing works
Stan, S. I., Biciuşcă, V., Clenciu, D., Mitrea, A., Boldeanu, M. V., Durand, P., & Dănoiu, S. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2629 · Cited by 11 · see citing works
Chai, S., Zhang, R., Ning, Z., Zheng, Y.-M., Rajpathak, S. N., & Ji, L. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i7.107335 · Cited by 10 · see citing works
Nani, A., Carrara, F., Paulesu, C. M. E., Fratte, C. D., Padroni, M., Enisci, S., Bilancio, M. C., Romio, M. S., Bertuzzi, F., & Pintaudi, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123958 · Cited by 10 · see citing works
Khaznadar, F., Petrovic, A., Khaznadar, O., Roguljić, H., Bojanić, K., Kuna, L., Siber, S., Smolić, R., Bilić-Čurčić, I., Wu, G. Y., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206561 · Cited by 12 · see citing works
Ren, Q., Tan, Y., Zhang, G., Dai, Y., Yang, L., Wu, Y., He, H., & Chen, J. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70021 · Cited by 9 · see citing works
Insulin resistance: mechanisms and therapeutic interventions
Yu, L., Qian, J., Li, X., Tian, M., Bai, X., Yang, J., Deng, R., Lu, C., He, X., Lü, A., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00408-5 · Cited by 9 · see citing works
Shi, R., Chai, K., Wang, H., Zhou, J., Yang, S., Li, J., Qiao, C., Sheng, X., Zhang, X., & Wu, J. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70002 · Cited by 9 · see citing works
Hossain, M. F., Khan, N. A., Rahman, A., Chowdhury, M. F. I., Bari, S., Khan, M. A., Masud, U. W., Zakia, U. B., Paul, S. P., & Tasnim, N. (2022) · Cureus · doi:10.7759/cureus.28367 · Cited by 8 · see citing works
Impact of SGLT2 Inhibitors on Lipoproteins in Type 2 Diabetes
Corral, P., Nardelli, N., Elbert, A. E., Aranguren, F., & Schreier, L. E. (2025) · Current Diabetes Reports · doi:10.1007/s11892-024-01572-0 · Cited by 7 · see citing works
Tan, Y., Qu, W., Zhao, J., Ma, Y., Zhang, Q., Gao, H., Zhen, Q., Wang, Y., Peng, Y., Liu, F., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101680 · Cited by 7 · see citing works
Patmore, L. A., Carey, I., Feld, J. J., Brouwer, W. P., Patel, K., Buti, M., Honkoop, P., Postma, D. F., Blokzijl, H., Koc, Ö. M., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70360 · Cited by 7 · see citing works
Erfanifar, A., Nikpour, S., Davoudi, Z., Jolfaei, P., Toreyhi, H., & Nasab, S. N. M. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02098-6 · Cited by 10 · see citing works
Yang, L., Ruan, J., Fang, Y., & Xu, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1667823 · Cited by 7 · see citing works
Ogawa, Y., Nakahara, T., Ando, Y., Yamaoka, K., Fujii, Y., Uchikawa, S., Fujino, H., Ono, A., Murakami, E., Kawaoka, T., et al. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002588 · Cited by 7 · see citing works
Kaur, S., Sojitra, V., Zahra, A., Hutchinson, J., Folawemi, O., Bittla, P., & Ramphall, S. (2023) · Cureus · doi:10.7759/cureus.45789 · Cited by 7 · see citing works
Esmaeili, A., Azar, R. P., Hosseiniazar, M. M., & Gharabagh, L. H. (2024) · Journal of General and Family Medicine · doi:10.1002/jgf2.723 · Cited by 8 · see citing works
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Koullias, E., & Koskinas, J. S. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00564 · Cited by 7 · see citing works
- Authors
- Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E.
- Affiliations
- Iran University of Medical Sciences (IR)
- Corresponding author
- Khamseh, Mohammad E.
- Venue
- Diabetes Therapy
- Published
- 2021-02-14
- Volume
- 12
- Issue
- 3
- Pages
- 843-861
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC7882235
- OpenAlex
- W3130225195
- Cited by
- 173
- References
- 86
- Citations by year
- 2026: 22 · 2025: 40 · 2024: 30 · 2023: 47 · 2022: 22 · 2021: 10
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Iran University of Medical Sciences
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- empagliflozin, pioglitazone, non-alcoholic fatty liver disease, type 2 diabetes, hepatic steatosis, liver fibrosis, controlled attenuation parameter, liver stiffness measurement, FibroScan, visceral fat, body composition, insulin resistance, SGLT2 inhibitors, thiazolidinediones, antidiabetic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
